It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Research collaboration covers multiple antibody research programs
He brings extensive cross-functional expertise built through leadership roles
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Subscribe To Our Newsletter & Stay Updated
